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From Melanoma Bridge Meeting 2014
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Background
In 2007, a phase 1 dose-escalation safety study of intratu-
moral electroporation (EP) of plasmid interleukin-12
(pIL-12) was completed in 24 patients (pts) with malignant
melanoma. IL-12 is thought to promote interferon-g-
pathway activation and antigen presentation and processing
machinery (APM) to enhance systemic anti-tumor
response. This phase 1 study was the first ever gene therapy
in humans to use EP to locally deliver DNA plasmid to
induce systemic anti-tumor immunity. Here we present
long-term overall survival (OS) results from this study.
Methods
Twenty-four pts with stage IIIB-IV melanoma and with at
least two accessible lesions received one treatment cycle of
pIL-12 EP administered on days 1, 5 and 8. Dose escala-
tion with increasing plasmid concentrations was per-
formed in cohorts 1 through 5. Plasmid was dispensed at
concentrations of 0.1, 0.25, 0.5, 1.0 and 1.6 mg/mL, and
plasmid volume was calculated based on tumor volume.
Two additional cohorts were enrolled (cohorts 6 and 7)
and received a total dose of 3.8 or 5.8 mg/treatment
respectively, divided among two to four tumor sites, irre-
spective of tumor volume. Tumor responses were evalu-
ated by modified RECIST. Biopsies were obtained for
tumor histology, including evaluation of lymphocytic infil-
trate, and tissue intratumoral IL-12 concentration.
Results
In this phase 1 study, 53% (10/19) pts with metastatic dis-
ease had a systemic response to the local pIL-12 EP treat-
ment as evidenced by stable disease or objective regression
of non-injected lesions. Additionally, 11% (2/19) experi-
enced complete regression of all distant lesions without
concurrent or subsequent systemic therapy. The most fre-
quent adverse event (AE) related to treatment was transi-
ent pain during the EP procedure, with 54% (13/24) pts
reporting grade 1 and 46% (11/24) pts reporting grade 2
pain. No DLT was noted within any of the treatment
cohorts. The median OS (n=24, ITT) was 24.2 mos. In pts
who experienced SD or better with pIL-12 EP (n=9), OS
of 46.4 mos was observed, a 32.9 mos increase compared
to non-responders (OS 13.5 mos; n=15).
Conclusions
Results from this phase 1 study demonstrate that local
treatment with pIL-12 EP successfully induces systemic
anti-tumor immune-mediated effects without severe local
or systemic toxicity. Moreover, long-term follow-up data
suggest that systemic disease stabilization with pIL-12 EP
is correlated with improved survival. Based on this evi-
dence, intratumoral EP of pIL-12 is an effective tool for
gene transfer of DNA plasmid with potential applications
as both a monotherapy and in combination with other
agents that promote anti-tumor immunity.
Authors’ details
1University of California, San Francisco – San Francisco, California, USA.
2OncoSec Medical Inc. – San Diego, California, USA. 3Old Dominion
University – Norfolk, Virginia, USA.
Published: 15 January 2015
doi:10.1186/1479-5876-13-S1-O3
Cite this article as: Daud et al.: Long-term overall survival from a phase
I trial using intratumoral plasmid interleukin-12 with electroporation in
patients with melanoma. Journal of Translational Medicine 2015
13(Suppl 1):O3.
2OncoSec Medical Inc. – San Diego, California, USA
Full list of author information is available at the end of the article
Daud et al. Journal of Translational Medicine 2015, 13(Suppl 1):O3
http://www.translational-medicine.com/content/13/S1/O3
© 2015 Daud et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
